From: Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases
After first dose | After second dose | |||||
---|---|---|---|---|---|---|
ADD (n = 162) | CG (n = 1545) | P value | ADD (n = 162) | CG (n = 1545) | P value | |
No symptoms | 72 (44.4) | 968 (62.7) | < 0.001 | 96 (59.3) | 1166 (75.5) | < 0.001 |
Local reaction | 55 (34.0) | 309 (20.0) | < 0.001 | 44 (27.2) | 253 (16.4) | < 0.001 |
Pain | 52 (32.1) | 292 (18.9) | < 0.001 | 42 (25.9) | 232 (15.0) | < 0.001 |
Redness | 2 (1.2) | 8 (0.5) | 0.244 | 1 (0.6) | 11 (0.7) | 0.721 |
Swelling | 2 (1.2) | 26 (1.7) | 0.919 | 2 (1.2) | 27 (1.7) | 0.872 |
Pruritus | 0 | 4 (0.3) | 1.000 | 0 | 3 (0.2) | 1.000 |
Malaise | 0 | 2 (0.1) | 1.000 | 0 | 1 (0.1) | 1.000 |
Systemic reactions | 51 (31.5) | 354 (22.9) | 0.015 | 30 (18.5) | 172 (11.1) | 0.005 |
Fever | 2 (1.2) | 28 (1.8) | 0.827 | 0 | 14 (0.9) | 0.448 |
Chills | 4 (2.5) | 8 (0.5) | 0.020 | 0 | 5 (0.3) | 1.000 |
Fatigue | 28 (17.3) | 151 (9.8) | 0.003 | 13 (8.0) | 77 (5.0) | 0.099 |
Headache | 8 (4.9) | 17 (1.1) | < 0.001 | 2 (1.2) | 5 (0.3) | 0.137 |
Vertigo | 10 (6.2) | 50 (3.2) | 0.054 | 4 (2.5) | 25 (1.6) | 0.633 |
Somnolence | 1 (0.6) | 25 (1.6) | 0.514 | 1 (0.6) | 10 (0.6) | 0.638 |
Vomiting | 2 (1.2) | 14 (0.9) | 0.987 | 1 (0.6) | 4 (0.3) | 0.393 |
Diarrhea | 3 (1.9) | 24 (1.6) | 0.967 | 2 (1.2) | 14 (0.9) | 0.987 |
Abdominal pain | 0 | 6 (0.4) | 1.000 | 0 | 3 (0.2) | 1.000 |
Stuffy nose | 3 (1.9) | 16 (1.0) | 0.583 | 2 (1.2) | 10 (0.6) | 0.721 |
Sore throat | 6 (3.7) | 27 (1.7) | 0.155 | 4 (2.5) | 16 (1.0) | 0.219 |
Cough | 1 (0.6) | 14 (0.9) | 0.946 | 3 (1.9) | 9 (0.6) | 0.178 |
Chest pain | 0 | 1 (0.1) | 1.000 | 0 | 0 (0.0) | 1.000 |
Cardiopalmus | 0 | 3 (0.2) | 1.000 | 0 | 3 (0.2) | 1.000 |
New or worsened muscle pain | 2 (1.2) | 15 (1.0) | 0.925 | 4 (2.5) | 13 (0.8) | 0.117 |
New or worsened joint pain | 1 (0.6) | 3 (0.2) | 0.329 | 1 (0.6) | 4 (0.3) | 0.393 |
Skin rash | 9 (5.6) | 19 (1.2) | < 0.001 | 6 (3.7) | 7 (0.5) | < 0.001 |